Sarcomatoid Mesothelioma

Sarcomatoid mesothelioma is the least common and most aggressive histological subtype of malignant mesothelioma, accounting for approximately 10–20% of all cases. It is characterized by elongated, spindle-shaped cells that resemble the cells found in sarcomas — cancers of connective tissue — making it particularly difficult to diagnose and distinguish from other spindle cell tumors.¹

Patients with sarcomatoid mesothelioma face the most challenging prognosis of any mesothelioma cell type. The median survival is approximately 6–8 months with treatment, significantly shorter than the 12–24 months typical of epithelioid mesothelioma. Sarcomatoid cells grow rapidly, spread aggressively to adjacent structures, and demonstrate marked resistance to standard chemotherapy regimens.²

The poor response to conventional treatment has made sarcomatoid mesothelioma a focus of ongoing clinical research. Notably, the combination of nivolumab and ipilimumab (approved by the FDA in 2020 for unresectable pleural mesothelioma) has shown particular promise for non-epithelioid histologies, including sarcomatoid cases, in the CheckMate 743 trial.³

Like all mesotheliomas, sarcomatoid mesothelioma is predominantly caused by asbestos exposure. Accurate pathological identification is critical because the cell type significantly influences treatment strategy, prognosis, and eligibility for clinical trials.

Sarcomatoid mesothelioma includes several recognized histological subtypes, each with distinct cellular patterns:

• Transitional — cells display features intermediate between epithelioid and sarcomatoid morphology; some pathologists classify this as a distinct subtype rather than a variant of biphasic mesothelioma
• Lymphohistiocytoid — a rare variant characterized by dense inflammatory infiltrates mixed with sarcomatoid tumor cells; this subtype may carry a somewhat better prognosis than other sarcomatoid variants and can be mistaken for lymphoma
• Desmoplastic — more than 50% of the tumor consists of dense, collagenous (scar-like) tissue with bland-appearing spindle cells; extremely difficult to distinguish from benign fibrous pleurisy on biopsy, often requiring multiple samples for diagnosis

The desmoplastic variant is particularly challenging to diagnose because it closely mimics reactive pleural fibrosis, and small biopsies may not capture the diagnostic features needed to confirm malignancy.

Sarcomatoid mesothelioma symptoms are similar to those of other mesothelioma cell types but may progress more rapidly due to the aggressive nature of the disease:

• Severe, progressive chest pain
• Worsening shortness of breath
• Rapid, unexplained weight loss
• Persistent fatigue and malaise
• Dry, nonproductive cough
• Pleural effusion (though less common than in epithelioid type)
• Palpable chest wall mass (more common with sarcomatoid than other types)
• Difficulty swallowing (dysphagia) if tumor invades the esophagus

Because sarcomatoid mesothelioma tends to invade adjacent structures more aggressively, patients may develop symptoms related to chest wall invasion, rib involvement, or extension into the mediastinum relatively early in the disease course.

Sarcomatoid mesothelioma shares the same primary causative agent as all mesothelioma types — exposure to asbestos:

• Occupational exposure — construction, shipyard work, industrial insulation, power plants, oil refineries, automotive brake and clutch repair
• Military service — particularly Navy veterans exposed to asbestos insulation on ships
• Secondary exposure — household contacts of asbestos workers
• Environmental exposure — proximity to asbestos mines or naturally occurring asbestos deposits

The latency period between asbestos exposure and sarcomatoid mesothelioma development is typically 20 to 50 years.

• Asbestos exposure — the primary risk factor, with heavier and longer exposure correlating with increased risk
• Fiber type — amphibole asbestos fibers (crocidolite, amosite, tremolite) are most strongly associated with mesothelioma
• Age — most patients are diagnosed between ages 60 and 80
• Sex — approximately 80% of mesothelioma cases occur in men
• Genetic susceptibility — BAP1 gene mutations may predispose individuals to mesothelioma development
• Prior radiation therapy — therapeutic radiation to the chest has been associated with mesothelioma in rare cases

Diagnosing sarcomatoid mesothelioma is among the most challenging tasks in oncologic pathology:

• Imaging — CT scan and PET-CT reveal pleural thickening, masses, or effusions; sarcomatoid mesothelioma may show more mass-like growth patterns than other types
• Tissue biopsy — large tissue samples are essential; fine-needle aspiration is typically insufficient due to the need to demonstrate tissue architecture. Thoracoscopic biopsy or open surgical biopsy is preferred
• Immunohistochemistry — sarcomatoid mesothelioma often shows diminished or absent staining for typical mesothelial markers (calretinin, CK5/6, WT1); pancytokeratin (AE1/AE3) positivity helps distinguish it from true sarcomas
• Differential diagnosis — must be distinguished from sarcomatoid carcinoma, fibrosarcoma, synovial sarcoma, malignant fibrous histiocytoma, and reactive fibrous pleurisy

Misdiagnosis is common, and pathological review by a specialist with mesothelioma expertise is strongly recommended. The desmoplastic variant in particular can require multiple biopsies and careful evaluation to confirm malignancy.⁴

Sarcomatoid mesothelioma of the pleura uses the same TNM staging system as other pleural mesotheliomas:

• Stage I — tumor limited to the pleura on one side
• Stage II — tumor involves the pleura and extends into the lung or diaphragm on the same side
• Stage III — locally advanced disease with invasion of chest wall, mediastinum, or pericardium, and/or regional lymph node involvement
• Stage IV — distant metastasis or involvement of the contralateral pleura

Due to its aggressive growth pattern, sarcomatoid mesothelioma is more frequently diagnosed at advanced stages (III and IV), which limits surgical options.

Treatment of sarcomatoid mesothelioma is challenging due to its resistance to conventional therapies:

• Surgery — generally less effective for sarcomatoid mesothelioma. Most major cancer centers consider pure sarcomatoid histology a relative contraindication to aggressive surgical resection (EPP or P/D) because the high recurrence rate outweighs surgical benefits. However, selected patients with limited disease may still benefit from surgery
• Chemotherapy — the standard cisplatin/pemetrexed combination has limited efficacy in sarcomatoid mesothelioma, with response rates significantly lower than for epithelioid cases²
• Immunotherapy — nivolumab plus ipilimumab has shown the most promising results for sarcomatoid and non-epithelioid mesothelioma. The CheckMate 743 trial demonstrated a significant survival benefit for non-epithelioid patients, with median overall survival of 18.1 months versus 8.8 months with chemotherapy³
• Radiation therapy — used palliatively for pain management and to slow local tumor growth; may also be used prophylactically at biopsy or surgical sites to prevent tumor seeding
• Clinical trials — patients with sarcomatoid mesothelioma should be actively encouraged to explore clinical trials, as emerging therapies (targeted agents, novel immunotherapy combinations) may offer meaningful benefit

Sarcomatoid mesothelioma carries the most guarded prognosis of all mesothelioma cell types:

• Median survival is approximately 6–8 months with treatment
• One-year survival rates are significantly lower than for epithelioid mesothelioma
• The lymphohistiocytoid variant may have a somewhat more favorable prognosis than other sarcomatoid subtypes
• Immunotherapy (nivolumab + ipilimumab) has demonstrated the most meaningful survival improvement for this cell type
• Early-stage disease, younger age, and good performance status are associated with better outcomes even within this challenging category

The emergence of immunotherapy as a treatment option has provided meaningful hope for sarcomatoid mesothelioma patients who previously had very limited options.

Prevention strategies for sarcomatoid mesothelioma are the same as for all mesothelioma types:

• Elimination of occupational asbestos exposure through regulatory compliance
• Professional asbestos abatement in older buildings
• Proper respiratory protection in at-risk work environments
• Medical surveillance for individuals with known asbestos exposure
• Awareness campaigns targeting high-risk occupational groups